IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE...
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE...
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA®PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS...
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the...
Highlights: Record monthly Travelan® salesAustralian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales)MELBOURNE, Australia, Sept....
Significant progress made and well positioned for future growthLONDON, UK / ACCESSWIRE / September 13, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),...
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8...
Halifax, Nova Scotia--(Newsfile Corp. - September 11, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona")...
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:...
NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell ShuttleCollaboration to...
The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the...
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership...
Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim...
SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage...
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will...
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...